Filing Analysis
Quoin Pharmaceuticals entered into a $50.0 million private placement agreement with institutional investors, involving the issuance of 6.3 million ADSs and accompanying warrants. The deal includes significant dilution through pre-funded and ordinary warrants and contains a standstill provision preventing further equity financing for at least 90 days.
🚩 Red Flags
- Significant potential dilution from the issuance of over 3.1 million warrant ADSs.
- Equity financing standstill prevents the company from raising additional capital for at least 90 days.
- Warrants include a 'cashless exercise' provision if a registration statement is not effective within 6 months.
- The offering includes pre-funded warrants with a nominal exercise price ($0.0001), which is highly dilutive.
📋 Key Facts
- Total gross proceeds of up to $50.0 million ($30.8M upfront, $19.2M via warrant exercise).
- Issuance of 6,305,300 American Depositary Shares (ADSs) and accompanying ordinary warrants.
- Unit Purchase Price set at $4.88 per ADS/Warrant combo.
- Ordinary Warrants have an exercise price of $6.10 per ADS.
- Pre-funded warrants have an exercise price of $0.0001 per ADS.
- Company expects net proceeds of ~$29.0 million to fund operations into H2 2029.
- Includes a 90-day equity financing standstill period.
- Insiders (directors and officers) participated in the offering for ~$280,000.
Quoin Pharmaceuticals, Ltd. held its 2026 Annual General Meeting of Shareholders on August 20, 2026. Shareholders approved the election of directors, executive compensation, changes to the 401(k) plan, and the appointment of CBIZ CPAs P.C. as the independent auditor.
📋 Key Facts
- Annual Meeting held on August 20, 2026.
- Shareholders elected seven directors, including Dr. Michael Myers and Denise Carter.
- Shareholders approved the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm.
- Shareholders approved advisory compensation for named executive officers.
- Shareholders approved amendments to the Non-Employee Director (NED) Program, increasing the annual base retainer up to $250,000 and option awards between $20,000 and $200,000.
- Shareholders approved changes to the 401(k) plan matching contributions.
Quoin Pharmaceuticals, Ltd. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a formal transmission of the company's quarterly earnings press release.
📋 Key Facts
- Report date: August 14, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes Exhibit 99.1 containing the official press release of financial results.
- Company is listed on Nasdaq under ticker QNRX.
Quoin Pharmaceuticals announced that the FDA has conditionally approved 'QYLEKI™' as the proposed brand name for its investigational product QRX003, intended to treat Netherton Syndrome. This is a regulatory milestone regarding proprietary naming ahead of a planned New Drug Application (NDA).
📋 Key Facts
- FDA granted conditional approval for the brand name 'QYLEKI™' for the drug candidate QRX003.
- QRX003 is being developed to treat Netherton Syndrome.
- The company intends to include this proprietary name in its upcoming New Drug Application (NDA).
- Announcement date: June 23, 2026.
Quoin Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation to its QRX003 lotion (4%) for the treatment of Netherton Syndrome.
📋 Key Facts
- Orphan Drug Designation granted by Japan's MHLW for QRX003 lotion (4%)
- Target indication is Netherton Syndrome, a rare genetic skin disorder with no current approved treatments
- Designation provides incentives including priority review, tax incentives, and up to 10 years of market exclusivity upon approval
- The announcement was made via press release on June 4, 2026
Quoin Pharmaceuticals, Ltd. announced its first quarter 2026 financial results on May 7, 2026. The filing serves as a formal notice of the earnings release, with the detailed financial data contained in the attached press release exhibit.
📋 Key Facts
- The filing was made on May 7, 2026, reporting results for the first quarter of 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Quoin Pharmaceuticals is an Israeli-incorporated company with principal executive offices in Ashburn, VA.
- The company's American Depositary Shares (ADS) each represent thirty-five (35) Ordinary Shares.
Quoin Pharmaceuticals, Ltd. announced its financial results for the fourth quarter and fiscal year ended 2025. The filing includes a press release detailing the company's financial performance and operational status as of March 26, 2026.
📋 Key Facts
- The company reported Q4 and full-year 2025 financial results on March 26, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release was included as Exhibit 99.1.
- The registrant is an Israeli-incorporated company with American Depositary Shares (ADSs) listed on Nasdaq (QNRX).
Quoin Pharmaceuticals announced that the FDA has granted Fast Track Designation to its lead candidate, QRX003 lotion (4%), for the treatment of Netherton Syndrome. This designation is intended to expedite the development and review process for therapies addressing serious conditions with unmet medical needs.
📋 Key Facts
- On March 11, 2026, the FDA granted Fast Track Designation to QRX003 lotion (4%).
- The target indication is Netherton Syndrome, a rare and severe genetic skin disorder with no currently approved treatments.
- Fast Track benefits include more frequent FDA interactions, eligibility for rolling review, and potential qualification for Accelerated Approval and Priority Review.
- The announcement was made via a press release furnished under Item 7.01 and Item 8.01.
Quoin Pharmaceuticals has filed an application for Breakthrough Medicine Designation with the Saudi Food and Drug Authority (SFDA) for its lead candidate, QRX003, intended to treat Netherton Syndrome. If granted, this could accelerate regulatory review and potentially allow patient access in Saudi Arabia as early as H2 2026.
🚩 Red Flags
- Clinical trial outcomes are subject to risk; failure to meet endpoints would jeopardize the entire regulatory strategy mentioned in the filing.
📋 Key Facts
- Filed application for SFDA Breakthrough Medicine Designation for QRX003 (topical treatment for Netherton Syndrome).
- QRX003 is currently in two late-stage whole-body pivotal clinical trials; enrollment expected to complete H1 2026.
- Top-line clinical data anticipated in H2 2026.
- Company plans to submit a US NDA and other territory applications in late 2026/early 2027, contingent on clinical success.
- QRX003 already holds Orphan Drug and Pediatric Rare Disease Designations from the FDA and Orphan Drug Designation from the EMA.
- Established distribution partnership with Genpharm for Saudi Arabia and MENA countries.
Quoin Pharmaceuticals, Ltd. announced that its Compensation Committee has approved new forms of award agreements for the grant of stock options to directors and executive officers under the company's 2025 Equity Incentive Plan.
🚩 Red Flags
- None identified in this filing
📋 Key Facts
- Approval date: November 14, 2025
- Plan name: 2025 Equity Incentive Plan
- Award types include Incentive Stock Options and Non-Qualified Stock Options
- Includes provisions for 'Cashless Exercise Mechanism' and various payment methods (cash, wire, etc.)
- Termination provisions specify different treatments for death/disability, termination for cause, and other terminations.
Quoin Pharmaceuticals announced the successful achievement of target loading concentrations for its two topical rapamycin delivery technologies (4% w/w formulation and 5% w/w dermal patch). The company intends to begin manufacturing clinical trial batches in Q4 2025 with a goal of starting clinical testing in 1H 2026.
🚩 Red Flags
- No current FDA-approved treatments exist for the identified target indications, implying high regulatory risk/uncertainty in future trials.
📋 Key Facts
- Achieved 4% w/w rapamycin loading concentration for proprietary topical formulation.
- Achieved 5% w/w rapamycin concentration for proprietary dermal patch system.
- Manufacturing of clinical trial and stability batches planned for Q4 2025.
- Clinical testing targeted to commence in the first half (1H) of 2026.
- Initial clinical indications include Microcystic Lymphatic Malformations and Venous Malformations.
Quoin Pharmaceuticals, Ltd. announced its third quarter financial results for the period ending in 2025. The filing serves as a formal notice of the release of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Third Quarter (Q3) financial results
- Ticker: QNRX (Nasdaq)
- Company status: Reporting entity under Section 13 or 15(d) of the Exchange Act
Quoin Pharmaceuticals announced that the FDA has granted Orphan Drug Designation to its lead product candidate, QRX003, for the treatment of Netherton Syndrome. This follows a similar designation from the EMA in May 2025.
📋 Key Facts
- FDA granted Orphan Drug Designation for QRX003 (Netherton Syndrome) on October 21, 2025.
- EMA previously granted Orphan Drug Designation in May 2025.
- QRX003 is currently in two late-stage pivotal clinical trials.
- Enrollment for pivotal studies is expected to complete in Q1 2026.
- Top-line data from trials is anticipated in H2 2026.
- NDA submission is planned for later in 2026.
Quoin Pharmaceuticals completed a $16.6 million private placement of ADSs and various warrant series, including pre-funded warrants with a nominal exercise price. The offering includes significant contingent warrants tied to FDA milestones for their lead candidate QRX003.
🚩 Red Flags
- Significant dilution risk due to a large number of warrants and pre-funded warrants with extremely low exercise prices ($0.0001).
- The issuance of 'Pre-Funded Warrants' is often used as a substitute for equity when the company cannot meet minimum price requirements, effectively acting as immediate dilution.
- Contingent warrant structures create massive potential overhang that could dilute existing shareholders significantly upon clinical success.
📋 Key Facts
- Gross proceeds from the private placement: approximately $16.6 million; Net upfront proceeds: approximately $15 million.
- Securities issued include 15,152 ADSs and 1,993,939 Pre-Funded Warrants (exercise price of $0.0001 per ADS).
- Multiple series of Ordinary Warrants (Series H, I, J, K) were issued with exercise prices ranging from $9.075 to $12.375.
- Warrant exercise is tied to clinical/regulatory milestones: FDA Type C meeting minutes, primary endpoint achievement in pivotal trials, and FDA approval/PRV sale.
- Potential future cash proceeds from warrant exercises estimated at up to $88 million (total gross potential of $104.6 million).
- Director Dennis Langer participated in the offering, purchasing ~$128,641 worth of securities.
Quoin Pharmaceuticals, Ltd. announced the formalization of a separation agreement with former CFO Gordon Dunn, following his departure on August 15, 2025. The agreement includes significant cash severance and an extension for exercising stock options.
🚩 Red Flags
- Departure of the Chief Financial Officer (CFO) can sometimes signal internal friction or financial reporting concerns, though here it is characterized as a 'mutual separation'.
- Significant cash outflow for severance ($433k + $108k bonus) in a micro-cap context.
📋 Key Facts
- Gordon Dunn's last day as CFO was August 15, 2025.
- The company will pay $433,620 in bi-weekly installments in lieu of a 12-month notice period.
- A bonus of $108,405 for the 2024 financial year is to be paid as a lump sum on August 15, 2026.
- The post-termination exercise period for vested non-qualified stock options was extended from 90 days to 1 year and 9 months.
Quoin Pharmaceuticals held its 2025 Annual General Meeting, resulting in the election of directors and approval of several corporate governance items. Notably, the company appointed a new CFO who is the niece of the Company's Chairman and CEO.
🚩 Red Flags
- Related-party transaction/appointment: The newly appointed CFO, Sally Lawlor, is the niece of the CEO/Chairman, Dr. Michael Myers.
- Massive increase in authorized share capital (from 100M to 5B shares) suggests significant potential dilution for existing shareholders.
📋 Key Facts
- Annual General Meeting held on August 21, 2025; seven proposals were voted upon.
- Shareholders approved an amendment to increase authorized ordinary share capital from 100,000,000 to 5,000,000,000 shares.
- Sally Lawlor appointed as new CFO, Principal Financial Officer, and Principal Accounting Officer effective August 18, 2025.
- New CFO Sally Lawlor is the niece of Dr. Michael Myers, the Company's Chairman and CEO.
- CBIZ CPAs P.C. was appointed as the independent registered public accounting firm until the 2026 AGM.
- The company approved a new Compensation Policy for Executive Officers and Directors and a 2025 Equity Incentive Plan.
Quoin Pharmaceuticals, Ltd. announced its second quarter financial results for the period ending in 2025 via an 8-K filing on August 7, 2025.
📋 Key Facts
- Company reported Q2 financial results on August 7, 2025.
- The filing includes a press release as Exhibit 99.1.
- The report was signed by CEO Dr. Michael Myers.
Quoin Pharmaceuticals, Ltd. announced the mutual separation of its Chief Financial Officer, Gordon Dunn, effective later this year once a successor is appointed.
🚩 Red Flags
- Departure of a key C-suite executive (CFO) can signal internal friction or financial instability, though described here as 'mutual'.
📋 Key Facts
- Effective Date: Mutual separation agreed upon on July 3, 2025.
- Officer: Gordon Dunn, Chief Financial Officer.
- Transition Plan: Mr. Dunn will remain in his role until a successor is appointed.
- Compensation: The company anticipates entering into a separation agreement with the departing officer.
Quoin Pharmaceuticals announced that the FDA has granted Rare Pediatric Disease (RPD) Designation for its lead asset, QRX003, intended for the treatment of Netherton Syndrome. This is a regulatory milestone for the company's clinical-stage pipeline.
📋 Key Facts
- FDA granted Rare Pediatric Disease (RPD) Designation for lead asset QRX003.
- Target indication: Netherton Syndrome.
- The company is in late clinical-stage development.
Quoin Pharmaceuticals Ltd. has announced the scheduled date for its 2025 Annual General Meeting (AGM) as August 21, 2025. Due to the timing of this meeting relative to the previous year's AGM, the company is providing updated deadlines for shareholder proposals and proxy solicitations.
📋 Key Facts
- The 2025 Annual General Meeting (AGM) is scheduled for August 21, 2025.
- Shareholder proposals under Rule 14a-8 must be received by the Company by June 30, 2025, to be considered timely for inclusion in proxy materials.
- Shareholders intending to solicit proxies for director nominees other than the Company's nominees must provide notice by June 30, 2025, per Rule 14a-19.
Quoin Pharmaceuticals, Ltd. announced the approval of 2024 annual cash bonuses for its CEO, Dr. Michael Myers, and COO, Ms. Denise Carter.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- The Compensation Committee approved 2024 annual cash bonuses on May 29, 2025.
- Dr. Michael Myers (CEO) was awarded a bonus of $331,238.
- Ms. Denise Carter (COO) was awarded a bonus of $264,640.
- Bonuses are consistent with the CEO and COO Compensation Programs approved at the 2024 annual meeting on December 5, 2024.
Quoin Pharmaceuticals announced that it has received FDA clearance to begin a pivotal clinical study (CL-QRX003-002) for its lead product, QRX003, targeting Netherton Syndrome. This represents a significant regulatory milestone in the development of their primary asset.
📋 Key Facts
- FDA has cleared the initiation of second pivotal clinical study CL-QRX003-002.
- The study is for the company's lead product, QRX003.
- The indication being studied is Netherton Syndrome.
Quoin Pharmaceuticals, Ltd. announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its lead product candidate, QRX003, intended for the treatment of Netherton Syndrome.
📋 Key Facts
- Lead product: QRX003
- Indication: Netherton Syndrome
- Regulatory milestone: Orphan Drug Designation granted by the European Medicines Agency (EMA)
- Date of event: May 20, 2025
Quoin Pharmaceuticals, Ltd. announced its first quarter 2025 financial results on May 13, 2025. The filing serves as a formal notification of the release of quarterly earnings via an attached press release.
📋 Key Facts
- Reported date: May 13, 2025
- Reporting period: First Quarter 2025
- Filing type: Item 2.02 (Results of Operations and Financial Condition)
- Ticker: QNRX (Nasdaq)
Quoin Pharmaceuticals, Ltd. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per ADS. The company was previously in violation but maintained a closing bid price at or above the threshold between April 9 and April 28, 2025.
🚩 Red Flags
- Recent history of being below the minimum bid price requirement (delisting risk realized in the past month).
📋 Key Facts
- Received written notice from Nasdaq Listing Qualifications staff on April 29, 2025.
- Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price requirement.
- Compliance was maintained via closing bid prices of $1.00 or greater from April 9 to April 28, 2025.
- Nasdaq has notified the company that the compliance matter is now closed.
Quoin Pharmaceuticals Ltd. (QNRX) has approved a 1-for-35 reverse stock split of its American Depositary Shares (ADSs). The action is intended to boost the share price to meet Nasdaq's $1.00 minimum bid requirement and avoid delisting.
🚩 Red Flags
- Reverse stock split (often a sign of extreme price depreciation and distress).
- Imminent risk of Nasdaq delisting due to non-compliance with minimum bid requirements.
- The company explicitly states there is no assurance that this split will successfully maintain the listing.
📋 Key Facts
- Ratio Change: 1 ADS for every 35 existing ADSs.
- Effective Date: Market opening on April 9, 2025.
- Objective: To comply with Nasdaq's $1.00 minimum bid price requirement.
- New CUSIP: 74907L409 for the ADS following the split.
- The Ordinary Shares of the Company will not be affected by this adjustment; only ADSs are subject to the split.
Quoin Pharmaceuticals Ltd. (QNRX) has approved a 1-for-20 reverse stock split of its American Depositary Shares (ADSs). The action is intended to increase the share price to comply with Nasdaq's $1.00 minimum bid requirement and avoid delisting.
🚩 Red Flags
- Reverse stock split (often a sign of extreme downward price pressure)
- Imminent threat of Nasdaq delisting due to non-compliance with minimum bid requirements
- Potential for further dilution or volatility following the adjustment
📋 Key Facts
- The ratio change will be a 1-for-20 reverse split of issued and outstanding ADSs.
- Effective date for the Ratio Change is the market opening on April 8, 2025.
- The objective is to comply with Nasdaq's $1.00 minimum bid price requirement.
- New CUSIP number for the ADS following the change will be 74907L409.
- Ordinary Shares remain unaffected; only ADSs are subject to the split.
Quoin Pharmaceuticals announced positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study regarding the product QRX003. The report highlights significant improvements in skin healing and sleep quality for a pediatric patient after 6 weeks of treatment.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- QRX003 demonstrated near-complete skin healing after 6 weeks of whole body application in a pediatric Netherton Syndrome subject.
- The patient no longer requires antibiotics, antivirals, antihistamines, or glucocorticoids.
- Pruritus (itch) is almost completely eliminated, resulting in the first period of uninterrupted sleep for the patient.
- No adverse events have been reported after 6 weeks of whole body treatment.
- The Company expects to initiate whole body application on a second pediatric Netherton patient within a few weeks.
Quoin Pharmaceuticals, Ltd. announced the resignation of its independent auditor, Marcum LLP, and the appointment of CBIZ CPAs P.C. as its new independent registered public accounting firm for the fiscal year ending December 31, 2025.
🚩 Red Flags
- Auditor change in a micro-cap company can sometimes precede financial restatements or internal control issues, though no disagreements were reported here.
📋 Key Facts
- Marcum LLP resigned as the Company's independent auditor effective March 18, 2025.
- CBIZ CPAs P.C. has been engaged to serve as the new independent auditor for the fiscal year ending December 31, 2025.
- The change is driven by CBIZ CPAs acquiring Marcum's attest business effective November 1, 2024.
- Marcum reported no disagreements with the Company regarding accounting principles or auditing procedures during their tenure (FY2023, FY2024, and interim 2025).
- The Audit Committee of the Board of Directors approved the engagement of CBIZ CPAs.
Quoin Pharmaceuticals, Ltd. announced its fourth quarter and fiscal year 2024 financial results on March 13, 2025.
📋 Key Facts
- Company released Q4 and FY 2024 financial results via press release on March 13, 2025.
- The filing is an Item 2.02 report regarding Results of Operations and Financial Condition.
Quoin Pharmaceuticals announced highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. The first pediatric patient showed significant improvement in skin healing and pruritus after two weeks of QRX003 whole-body application.
🚩 Red Flags
- The data is based on a single pediatric patient ('First Pediatric Patient'), which represents an extremely small sample size for clinical validation.
📋 Key Facts
- Clinical endpoints: Investigator’s Global Assessment (IGA) improved from 7 to 1–2; Pruritus score improved from 5 to 1 on a 0-10 scale.
- Treatment duration for observed results: Two weeks of whole-body application of QRX003.
- Patient outcomes: Discontinuation of antihistamines, glucocorticoids, and antivirals; zero nightly sleep disturbances reported.
- Safety: No adverse events reported to date in the described patient case.
Quoin Pharmaceuticals has launched the 'NETHERTON NOW' awareness campaign to increase visibility for Netherton Syndrome, a rare genetic disease. The company is currently conducting four clinical studies for its lead candidate, QRX003.
📋 Key Facts
- Launched 'NETHERTON NOW' campaign/website (nethertonnow.com) to raise awareness for Netherton Syndrome.
- Company is conducting four ongoing clinical studies evaluating the safety and efficacy of QRX003 in Netherton Syndrome patients.
- Claims recent clinical data has underscored product potential, including photographic evidence of skin improvement after 12 weeks of dosing.
- As of February 4, 2025, the company has 20,585,830 outstanding ordinary shares (represented by ADS).
Quoin Pharmaceuticals announced clinical data from its open-label study of QRX003 for Netherton Syndrome. The data shows significant symptom improvement during the 12-week treatment period, which was completely reversed upon discontinuation of the drug.
🚩 Red Flags
- The reversal of efficacy upon discontinuation suggests the treatment may only manage symptoms rather than provide a long-term cure or disease modification.
📋 Key Facts
- Clinical data released on January 23, 2025, regarding QRX003 efficacy in Netherton Syndrome.
- M-IASI score improved from a baseline of 18 to 'Almost Clear' at 12 weeks of treatment.
- WINRS (itch scale) improved from 7 (baseline) to 2 at the end of the 12-week treatment period.
- IGA assessment moved from 'Moderate' to 'Almost Clear' during the treatment phase.
- All clinical benefits were completely reversed by week 4 post-discontinuation, with M-IASI returning to baseline (18) and WINRS returning to baseline (8).
Quoin Pharmaceuticals announced positive clinical data from its ongoing 12-week Investigator Pediatric Study for Netherton Syndrome. The subject showed significant improvement in skin assessment (IGA) and is being transitioned to whole-body application due to efficacy.
📋 Key Facts
- Clinical study: Ongoing 12-week Investigator Pediatric Study for Netherton Syndrome.
- Efficacy result: Subject's IGA assessment improved from 'severe' at baseline to 'mild-moderate' after 12 days, and 'Mild' after six weeks of dosing.
- Dosing change: Due to positive results, the subject is transitioning from 20% Body Surface Area (BSA) application to whole BSA application.
- Safety profile: No adverse events or safety concerns reported for this subject to date.
Quoin Pharmaceuticals announced positive interim clinical data from its ongoing open-label study for QRX003 in treating Netherton Syndrome. The 12-week data for the first subject showed significant improvement across all primary clinical endpoints, including skin severity and itch scales.
🚩 Red Flags
- Data is based on a single subject (n=1), which lacks statistical significance for broad clinical efficacy.
📋 Key Facts
- Clinical endpoint M-IASI improved from a baseline of 18 to 3 at 12 weeks.
- Worst Itch Numeric Rating Scale (WINRS) improved from 7 to 2 over the 12-week period.
- Investigator’s Global Assessment (IGA) moved from 'Moderate' to 'Almost Clear'.
- No safety concerns were reported for the subject during the study period.
- The data represents the completion of testing for the first subject in an open-label, twice-daily dosing study.
Quoin Pharmaceuticals completed a public offering of ADSs, Series F Warrants, Series G Warrants, and Pre-Funded Warrants on December 23, 2024. The offering raised approximately $6.8 million in gross proceeds to fund general corporate purposes and R&D.
🚩 Red Flags
- Significant dilution: The issuance of over 15 million Series F/G warrants and nearly 12 million pre-funded warrants represents massive potential future dilution.
- Warrant Overhang: Total number of potentially issuable shares via new and amended warrants is extremely high relative to the ADS offering size.
- Pre-Funded Warrants: Use of pre-funded warrants with near-zero exercise prices ($0.0001) is often a sign of distressed financing used when traditional equity markets are unavailable.
📋 Key Facts
- Completed public offering of 3,137,778 Ordinary Shares (ADSs).
- Issued 15,111,110 Series F Warrants (2-year expiration) and 15,111,110 Series G Warrants (5-year expiration).
- Issued 11,973,332 Pre-Funded Warrants with an exercise price of $0.0001.
- Aggregate gross proceeds: approximately $6.8 million.
- Combined offering price for ADS + Warrants: $0.45 per unit.
- Officers and directors purchased 1,333,333 ADSs and accompanying warrants for ~$600,000.
- Maxim Group LLC acted as the exclusive placement agent (7% cash fee).
- Amended prior warrants to reduce exercise price to $0.45 and extend expiration to Dec 23, 2029.
Quoin Pharmaceuticals announced FDA clearance to initiate a new clinical study for its topical lotion, QRX003, targeting Netherton Syndrome (NS). This study is notable for being the most extensive application of the drug to date, covering up to 80% of body surface area.
🚩 Red Flags
- Forward-looking statements include risks regarding the need to raise additional funds sooner than planned.
📋 Key Facts
- FDA clearance obtained to initiate a new clinical study for QRX003 in patients with Netherton Syndrome (NS).
- The study will be led by Dr. Amy Paller of Northwestern University.
- Study design involves applying QRX003 twice daily to >80% of the subject's body surface area over a 12-week period.
- Up to eight subjects are expected to be enrolled in this specific study.
- Data from this study is intended to supplement the regulatory data package for potential NDA filing.
Quoin Pharmaceuticals held its 2024 Annual General Meeting on December 5, 2024, where shareholders approved several items including director elections and amendments to the Articles of Association. The filing also details the ratification of compensation programs for the CEO, COO, and CFO.
🚩 Red Flags
- High level of 'Broker Non-Votes' (1,274,513) across all proposals suggests significant non-participation or uninstructed shares in the voting process.
- Significant equity grants to executives at a low exercise price ($0.78) which may indicate potential dilution.
📋 Key Facts
- Annual Meeting held on December 5, 2024; results reported via 8-K filed Dec 10, 2024.
- Shareholders approved amendments to Articles of Association regarding special meeting provisions and quorum requirements (33.3% or 25% depending on status).
- CEO Dr. Michael Myers' compensation program was approved, including a $662,475 base salary (retroactive to Jan 1, 2024) and an option grant of 536,603 ADSs at $0.78.
- COO Denise Carter's compensation program was approved, including a $529,980 base salary (retroactive to Jan 1, 2024) and an option grant of 536,609 ADSs at $0.78.
- CFO Gordon Dunn's compensation was ratified: $433,620 base salary (retroactive to Jan 1, 2024) and 338,994 ADS options at $0.78.
- Marcum LLP was appointed as the Company’s auditor by shareholder vote.
- Non-employee director compensation was amended to include an annual base retainer of $82,500.
Quoin Pharmaceuticals, Ltd. announced its third quarter 2024 financial results on November 7, 2024. The filing serves as a formal notice of the earnings release via Item 2.02.
📋 Key Facts
- Reported date of earliest event: November 7, 2024
- Filing covers Q3 2024 financial results
- Company is listed on Nasdaq under ticker QNRX
Quoin Pharmaceuticals has been granted a second 180-day grace period by Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company must achieve a closing bid price of at least $1.00 for ten consecutive business days by April 28, 2025, or face delisting.
🚩 Red Flags
- Delisting notice: Failure to meet the $1.00 minimum bid price requirement.
- Potential for a reverse stock split, which is often viewed by markets as a sign of distress and can lead to further dilution or volatility.
- The company has already exhausted one 180-day grace period (from April 29, 2024, to October 28, 2024).
📋 Key Facts
- Nasdaq granted an additional 180-day grace period to cure the Minimum Bid Price Requirement deficiency.
- The new deadline to regain compliance is April 28, 2025.
- Compliance requires the ADS closing bid price to be at or above $1.00 for a minimum of ten consecutive business days.
- The company has already notified Nasdaq of its intention to cure the deficiency via a reverse stock split if necessary.
Quoin Pharmaceuticals Ltd. has announced the scheduled date for its 2024 Annual General Meeting of Shareholders (AGM) as December 5, 2024. Due to the meeting being held more than 30 days after the anniversary of the previous AGM, the company is providing updated deadlines for shareholder proposals and proxy solicitations.
📋 Key Facts
- The 2024 Annual General Meeting (AGM) is scheduled for December 5, 2024.
- Shareholder proposals under Rule 14a-8 must be received by the company by October 10, 2024, to be considered timely.
- Shareholders intending to solicit proxies in support of director nominees other than the company's nominees must provide notice by October 10, 2024, per universal proxy rules.
Quoin Pharmaceuticals, Ltd. announced its second quarter 2024 financial results on August 8, 2024. The filing serves as a formal notification of the release of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: August 8, 2024
- Filing date: August 13, 2024
- Subject matter: Second quarter 2024 financial results
- Ticker: QNRX (Nasdaq)
Quoin Pharmaceuticals received a notice from Nasdaq stating that its American Depositary Shares (ADSs) failed to maintain the minimum $1.00 closing bid price for 31 consecutive business days between March 14, 2024, and April 26, 2024. The company has been granted a 180-day compliance period ending October 28, 2024.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price ($1.00) for over 30 consecutive business days
📋 Key Facts
- Notice received from Nasdaq Listing Qualifications Department on April 29, 2024.
- Failure to meet the Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)) for 31 consecutive business days.
- Compliance period is 180 calendar days, expiring October 28, 2024.
- To regain compliance, ADS price must be at or above $1.00 for a minimum of ten consecutive business days during the compliance period.
Quoin Pharmaceuticals, Ltd. held a Special General Meeting on April 5, 2024, where shareholders approved the issuance of ordinary shares to Alumni Capital LP. This approval facilitates the conversion/issuance of ADSs pursuant to a previously signed purchase agreement dated January 25, 2024.
🚩 Red Flags
- Significant dilution risk as the issuance of shares to Alumni Capital LP has been authorized by shareholders.
- The vote was not unanimous, with a notable number of 'Against' votes (23,469).
📋 Key Facts
- Special General Meeting held on April 5, 2024.
- Shareholders approved the 'Alumni Issuance Proposal'.
- The proposal authorizes the issuance of ordinary shares represented by ADSs pursuant to a purchase agreement with Alumni Capital LP dated January 25, 2024.
- Voting results: 56,626 For; 23,469 Against; 2,338 Abstain.
Quoin Pharmaceuticals, Ltd. announced its financial results for the fourth quarter and full fiscal year 2023 on March 13, 2024.
📋 Key Facts
- Reported date: March 13, 2024
- Reporting period: Q4 and Fiscal Year 2023
- The filing includes a press release as Exhibit 99.1 containing detailed financial results.
Quoin Pharmaceuticals completed a $6.5 million public offering of ADSs and various warrants, including pre-funded warrants with a nominal exercise price of $0.0001. The company also negotiated amendments to existing warrants to reduce their exercise price to $1.60.
🚩 Red Flags
- Significant dilution risk due to the issuance of millions of warrants (Series D, E, and Pre-Funded) at low/nominal exercise prices.
- Pre-funded warrants with $0.0001 exercise price effectively act as immediate equity issuance upon conversion, causing massive dilution.
- Warrant amendments for existing holders to reduce exercise price to $1.60 suggests pressure from prior debt/equity holders or need to prevent expiration/litigation.
📋 Key Facts
- Completed a public offering of approximately $6.5 million on March 7, 2024.
- Securities issued include 811,250 Ordinary Shares (ADSs), 4,062,500 Series D Warrants, 4,062,500 Series E Warrants, and 3,251,250 Pre-Funded Warrants.
- Pre-Funded Warrants have an exercise price of $0.0001 per share and are immediately exercisable.
- Series D and E Warrants have an exercise price of $1.60 per share.
- The company entered into a standstill agreement prohibiting variable rate financings for 180 days and equity financings for 90 days.
- Placement Agent (A.G.P./Alliance Global Partners) received a 7.0% cash fee plus 1.0% non-accountable expenses and $125,000 in legal fee reimbursements.
Quoin Pharmaceuticals, Ltd. announced the formal termination of Contingent Value Rights (CVRs) related to the 2021 sale of Cellect Biotherapeutics Ltd. to EnCellX, Inc. The company previously held no interest in these CVRs as they were distributed directly to former shareholders.
📋 Key Facts
- On February 29, 2024, the acting CEO of EnCellX, Inc. certified that the CVRs are terminated.
- The CVRs originated from a business spin-out/sale during the October 28, 2021 merger between Cellect Biotechnology Ltd. and Quoin Inc.
- Quoin Pharmaceuticals (the Company) was never entitled to receive net proceeds from these CVRs, meaning no assets or liabilities were recorded on its balance sheet.
Quoin Pharmaceuticals entered into a $8 million equity line of credit (Purchase Agreement) with Alumni Capital LP. The agreement allows the company to issue American Depositary Shares (ADSs) at a discount to market prices to raise working capital.
🚩 Red Flags
- Equity dilution: The agreement allows for the issuance of up to $8M in new shares, which will significantly dilute existing shareholders.
- Discounted pricing: Shares are being sold at a significant discount (up to 10% below VWAP) to provide immediate liquidity.
- High minimum commitment: The company is contractually obligated to sell at least $4,000,000 in securities, reducing its control over timing and dilution management.
📋 Key Facts
- Entered into Purchase Agreement with Alumni Capital LP on January 25, 2024.
- Total commitment amount of up to $8,000,000 in newly issued ordinary shares (ADSs).
- The company is obligated to issue at least $4,000,000 of the total commitment before the end of the period.
- Pricing options include discounts to VWAP (90% or 98%) or a floor price of $1.00 per share.
- Issuance is subject to SEC registration and shareholder approval.
- Alumni Capital LP is prohibited from short selling or hedging the company's ADSs during the term.